** Shares of Chinese immunology diseases therapeutics developer Hbm Holdings Ltd 2142.HK rise 4.8% to HK$6.27, their highest since January 2022, and on course for second session of gains
** Hbm says co, as a licensor in a license agreement for product HBM9378/SKB378, has received an upfront payment from licensee Windward Bio AG, which will bolster co's cash reserves
** It gives no further details
** Hong Kong's healthcare index .HSCIH climbs 1.1%, Hang Seng Index .HSI rises 2.5%
** Stock up 221.5% YTD
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。